News

Aton Pharma Inc. has launched an authorized generic version of its timolol maleate ophthalmic gel-forming solution (Timoptic-XE). The non-selective beta-adrenergic receptor blocking agent is indicated in the treatment of elevated IOP in patients with ocular hypertension or open-angle glaucoma. The company also will continue to make available timolol maleate under the brand name.

According to an article in the February 2010 issue of the journal Annals of Epidemiology, a study of 180,000 patients showed that taking statins lowers the risk of cataract.

Dr. Patz remembered

Arnall Patz, MD, may not have had instant name recognition among most Americans, but among ophthalmologists, he was a legend.

Results from a pilot study suggest that topical treatment with the ribonucleotide GS-101 is safe for reducing corneal neovascularization in certain patient populations.

In this point-counterpoint overview, David S. Greenfield, MD, speaks in favor of trabeculectomy, whereas Dale K. Heuer, MD, argues the merits of tube shunts.

Early results from a clinical study of a non-incisional procedure indicate the approach produces substantial corneal flattening and improves visual outcomes.

An intracorneal inlay for the treatment of presbyopia uses the pinhole effect to increase depth of focus by selecting for the central light ray and minimizing refraction.

Preliminary results from a phase 1 safety and tolerability study show no dose-limiting toxicity so far in patients treated with intravitreal injections of volociximab in combination with anti-VEGF therapy for neovascular age-related macular degeneration.

University of Iowa's Department of Ophthalmology and Visual Sciences has long developed a reputation for educating its residents in a nurturing and supportive environment.

Optic atrophy is itself not a diagnosis, but a stepping stone for further work-up.

Results of the 2009 International Society of Refractive Surgery survey examining refractive surgery practice patterns in the United States show total surgical volume decreased while surgeons are continuing to embrace new techniques and technologies that can afford safer, more predictable outcomes.

Senior ophthalmologists with years of surgical experience have performed thousands of cataract surgeries and often know what they want from an ophthalmic viscosurgical device.

An excimer laser offers a number of features that collectively contribute to outstanding outcomes when using this platform to perform LASIK for a range of refractive errors.

Results from 3 years of follow-up in the phase II clinical trial investigating an angle-supported phakic IOL for the treatment of moderate to high myopia indicate this anterior chamber implant provides excellent visual acuity and is associated with accurate predictability of refraction and promising safety.

A neuroprotective approach to the treatment of glaucoma is not imminent, but several promising approaches are under investigation.

The safety and efficacy of cataract removal using torsional ultrasound with a proprietary handpiece and phacoemulsification system have been raised to a higher level by a recent software upgrade, according to one expert.

An intraocular device is a new concept in the treatment of age-related macular degeneration that taps into telescopic mirror technology to redesign patients' vision, according to experts.

Ranibizumab for the treatment of macular edema associated with central retinal vein occlusion demonstrated rapid and sustained improvement as early as 7 days after the start of treatment through 6-month interim analysis.